Drugs / Inactivated influenza H7N9 vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03318315 | Feb 2018 → Jul 2019 | avian influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT03312231 | Feb 2018 → Sep 2019 | avian influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Inactivated influenza H7N9 vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03318315 ↗ |
| Known as | 2017 H7N9 IIV | “2 doses of AS03-adjuvanted 2017 H7N9 IIV and one dose of seasonal influenza vaccine (IIV4)” NCT03318315 ↗ |
| Modality | Vaccine | “pre-pandemic 2017 monovalent inactivated influenza A/H7N9 virus vaccine” NCT03312231 ↗ |
| Route | Intramuscular | “administered intramuscularly” NCT03312231 ↗ |